Envoys Medical: Q2 net loss attributable to common stockholders was $0.07 per basic and diluted share

Envoy Medical, Inc. (NASDAQ: COCH) reported its second-quarter 2026 financial results, revealing a net loss of $0.07 per basic and diluted share. The company also announced key regulatory and clinical milestones, including the completion of the second quarter and progress in its pivotal clinical trial. Envoy Medical, a hearing health company focused on innovative technologies for hearing loss, highlighted positive 12-month data from its study of the fully implanted Acclaim® cochlear implant, an investigational device. The company remains committed to advancing its portfolio of fully implanted hearing solutions, including the Esteem® active middle ear implant, which has been commercially available since 2010. Investors and stakeholders are advised to review the quarterly earnings release and 10-Q filing for detailed financial and operational performance.